Title: Developing new targeting of enzyme therapies for lysosomal disease
Description of the Project:
A French start-up created in 2012 develops new therapeutic approach based on membrane receptor targeting and nanomaterials. The technology allows the targeting of drugs to lysosomes for therapies of lysosomal storage diseases or cancer. The company would like to establish new partnerships to develop lysosomal disease treatments combining enzyme replacement therapy with other therapeutics (gene therapy, chaperone,...) in order to make a joint proposal for EJP RD JTC2020 call for project.
Partner Sought: academic or private partners
Publicado por europa en febrero 4, 2020